Expertise in
12
conditions

Ans T. Van Der Ploeg-Van Der Graaf

Rotterdam, ZH, NL 
Expertise in
12
conditions
Rotterdam, ZH, NL 

Overview

Ans Van Der Ploeg-Van Der Graaf practices practicing medicine in Rotterdam, Netherlands.

Van Der Ploeg-Van Der Graaf is highly rated in 12 conditions, according to our data. Their clinical expertise encompasses Pompe Disease, Mucolipidosis Type 4, Mucopolysaccharidosis Type 6 (MPS VI, Maroteaux-Lamy Syndrome), Mucopolysaccharidoses (MPS), and Extracranial-Intracranial Bypass Surgery.

They are actively involved in clinical research, co-authoring 242 peer reviewed articles and participating in 2 clinical trials.

Locations

Rotterdam, ZH 3015GE, Netherlands
Other Locations
Amsterdam, NH, Netherlands
Netherlands
Leiden, ZH, Netherlands
Eindhoven, NB, Netherlands
Utrecht, UT, Netherlands
Leiderdorp, ZH 2353GA, Netherlands
Bilthoven, UT, Netherlands
Sint Maartenskliniek
Nijmegen, GE, Netherlands
Leidschendam, ZH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome
A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: DNL310
Study Phase: Phase 1/Phase 2
MPS VI Clinical Surveillance Program (CSP)
MPS VI Clinical Surveillance Program (CSP)
Enrollment Status: Completed
Publish Date: April 05, 2021
View 1 Less Clinical Trial

242 Total Publications

Author Correction: Domain-substituted IGF2 tag modulates targeting of lentiviral gene therapy for Hunter syndrome.
Author Correction: Domain-substituted IGF2 tag modulates targeting of lentiviral gene therapy for Hunter syndrome.
Journal: EMBO molecular medicine
Published: July 11, 2026

Frequently Asked Questions about Ans T. Van Der Ploeg-Van Der Graaf

Is Ans T. Van Der Ploeg-Van Der Graaf a top-rated expert for Pompe Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Ans T. Van Der Ploeg-Van Der Graaf is classified as an Elite expert for Pompe Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ans T. Van Der Ploeg-Van Der Graaf participate in research or clinical trials?

Yes. Ans T. Van Der Ploeg-Van Der Graaf has published 242 articles and abstracts on conditions like Pompe Disease. You can view a list of Ans T. Van Der Ploeg-Van Der Graaf's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Van Der Ploeg-Van Der Graaf's expertise for a condition
ConditionClose
View All 26 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile